{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T23:24:12Z","timestamp":1756682652157,"version":"3.41.2"},"reference-count":9,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented challenge. Meeting this has resulted in changes to working practices and the impact on the management of patients with heart failure with reduced ejection fraction (HFrEF) is largely unknown. We performed a retrospective, observational study contrasting patients diagnosed with HFrEF attending specialist heart failure clinics at a UK hospital, whose subsequent period of optimisation of medical therapy was during the COVID-19 pandemic, with patients diagnosed the previous year. The primary outcome was the change in equivalent dosing of ramipril and bisoprolol at 6-months. Secondary outcomes were the number and type of follow-up consultations, hospitalisation for heart failure and all-cause mortality. In total, 60 patients were diagnosed with HFrEF between 1 December 2019 and 30 April 2020, compared to 54 during the same period of the previous year. The absolute number of consultations was higher (390 vs 270; p = 0.69), driven by increases in telephone consultations, with a reduction in appointments with hospital nurse specialists. After 6-months, we observed lower equivalent dosing of ramipril (3.1 \u00b1 3.0 mg vs 4.4 \u00b1 0.5 mg; p = 0.035) and similar dosing of bisoprolol (4.1 \u00b1 0.5 mg vs 4.9 \u00b1 0.5 mg; p = 0.27), which persisted for ramipril (mean difference 1.0 mg, 95% CI 0.018\u20132.09; p = 0.046) and bisoprolol (mean difference 0.52 mg, 95% CI -0.23\u20131.28; p = 0.17) after adjustment for baseline dosing. We observed no differences in the proportion of patients who died (5.0% vs 7.4%; p = 0.59) or were hospitalised with heart failure (13.3% vs 9.3%; p = 0.49). Our study suggests the transition to telephone appointments and re-deployment of heart failure nurse specialists was associated with less successful optimisation of medical therapy, especially renin-angiotensin inhibitors, compared with usual care.<\/jats:p>","DOI":"10.31083\/j.rcm2202034","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T05:11:38Z","timestamp":1625461898000},"source":"Crossref","is-referenced-by-count":3,"title":["Impact of the COVID-19 pandemic on the management of chronic heart failure"],"prefix":"10.31083","volume":"22","author":[{"given":"Melanie","family":"McGinlay","sequence":"first","affiliation":[{"name":"Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS9 7TF Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Straw","sequence":"first","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Jagger","sequence":"first","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bako","family":"Nouri","sequence":"first","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gierula","sequence":"first","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus K","family":"Witte","sequence":"first","affiliation":[{"name":"Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016; 37: 2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Harkness A, Ring L, Augustine DX, Oxborough D, Robinson S, Sharma V, et al. Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography. Echo Research and Practice. 2020; 7: G1\u2013G18.","DOI":"10.1530\/ERP-19-0050"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Chatrath N, Kaza N, Pabari PA, Fox K, Mayet J, Barton C, et al. The effect of concomitant COVID\u201019 infection on outcomes in patients hospitalized with heart failure. ESC Heart Failure. 2020; 7: 4443\u20134447.","DOI":"10.1002\/ehf2.13059"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Raad M, Gorgis S, Dabbagh M, Parikh S, Cowger J. Characteristics and Outcomes of Patients with Heart Failure Admitted with Covid-19 in a Cohort Study from Southeast Michigan. Journal of Cardiac Failure. 2020; 26: S74.","DOI":"10.1016\/j.cardfail.2020.09.215"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Sankaranarayanan R, Hartshorne\u2010Evans N, Redmond-Lyon S, Wilson J, Essa H, Gray A, et al. The impact of COVID\u201019 on the management of heart failure: a United Kingdom patient questionnaire study. ESC Heart Failure. 2021; 8: 1324\u20131332.","DOI":"10.1002\/ehf2.13209"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Bromage DI, Cannat\u00e0 A, Rind IA, Gregorio C, Piper S, Shah AM, et al. The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. European Journal of Heart Failure. 2020; 22: 978\u2013984.","DOI":"10.1002\/ejhf.1925"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Colivicchi F, Di Fusco SA, Magnanti M, Cipriani M, Imperoli G. The Impact of the Coronavirus Disease-2019 Pandemic and Italian Lockdown Measures on Clinical Presentation and Management of Acute Heart Failure. Journal of Cardiac Failure. 2020; 26: 464\u2013465.","DOI":"10.1016\/j.cardfail.2020.05.007"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Straw S, McGinlay M, Relton SD, Koshy AO, Gierula J, Paton MF, et al. Effect of disease-modifying agents and their association with mortality in multi-morbid patients with heart failure with reduced ejection fraction. ESC Heart Failure. 2020; 7: 3859\u20133870.","DOI":"10.1002\/ehf2.12978"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Jim\u00e9nez-Blanco Bravo M, Cordero Pereda D, S\u00e1nchez Vega D, del Prado D\u00edaz S, Monteagudo Ruiz J, Zamorano G\u00f3mez J, et al. Heart Failure in the Time of COVID-19. Cardiology. 2020; 145: 481\u2013484.","DOI":"10.1159\/000509181"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/2\/10.31083\/j.rcm2202034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T17:01:54Z","timestamp":1732726914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/22\/2\/10.31083\/j.rcm2202034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"alternative-id":["1625013549659-1914570188"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2202034","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"article-number":"271"}}